

Identification of alterations in DNA copy number in host stromal cells during tumor progression

Robert J. Pelham^{*†‡}, Linda Rodgers[§], Ira Hall[§], Robert Lucito[§], Ken C. Q. Nguyen[§], Nicholas Navin[§], James Hicks[§], David Mu[§], Scott Powers[§], Michael Wigler[§], and David Botstein^{*†‡}

^{*}Lewis-Sigler Institute for Integrative Genomics and [†]Department of Molecular Biology, Princeton University, Princeton, NJ 08544; and [§]Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, NY 11724

Contributed by David Botstein, October 30, 2006 (sent for review September 13, 2006)

The interactions between cancer cells and the surrounding host stromal tissue play a critical role in tumor progression and metastasis, but the molecular nature of this relationship remains largely uncharacterized. Furthermore, although genetic changes of neoplastic cells in tumors contribute significantly to tumor progression, it is not known whether similar changes occur in the adjacent host stromal microenvironment and whether they contribute to or inhibit tumorigenesis. To address this question in an unbiased and genome-wide manner, we applied high-resolution DNA copy number analysis to murine stromal DNA isolated from human xenograft tumors that were formed in immunodeficient mice. We show that numerous amplifications and deletions are found within the host stromal microenvironment, suggesting that alterations in host DNA copy number can occur and may play a significant role in modifying tumor–stromal interactions.

cancer | stroma | microarray

It has long been understood that tumors are complex tissues. Genetically aberrant “cancer cells,” the ultimate cause of the tumor, are only one component of most epithelial tumors; other “stromal” components include cells of mesenchymal origin that have repeatedly been implicated as potential contributors to the growth of tumors (1, 2). Tumors frequently also contain many kinds of inflammatory cells, suggesting a connection between tumor growth and inflammation (3). Furthermore, the similarity between the cell populations and activities associated with normal wound healing and those found in tumors has often been noted (4, 5). In their influential review, Hanahan and Weinberg emphasize the possibility that stromal contributions may be vital to the growth of tumors, and go so far as to suggest that “. . . in some tumors, these cooperating cells may eventually depart from normalcy, co-evolving with their malignant neighbors to sustain the growth of the latter” (1).

Genome-scale comprehensive gene expression studies of solid tumors have served to illustrate in striking detail the complexity of tumors and the diversity of nonepithelial cell types they contain. The earliest studies noted that gene expression profiles characteristic of stromal and inflammatory cells are usually detected, as are expression signatures previously associated with wound healing and angiogenesis (4, 6, 7). These and subsequent studies of many different tumor types provided a mass of detailed information, leading to three general observations. First, each anatomical type of cancer is associated with recognizable expression pattern usually closely related to the pattern seen in normal tissues; some types (e.g., breast cancer) are classifiable into a small family of “subtypes” (6, 8, 9). Second, within a cancer “subtype,” the tumors of each individual nevertheless remain distinguishable by differences in gene expression pattern. These patterns are the sum of gene expression in the genetically deranged and the stromal cells comprising the tumor. Third, the expression profiles of distant metastases tend to be even more similar to those of the primary tumor than primary tumors of the same subtype are to each other (breast, refs. 6 and 10; lung, ref. 7; gastric, ref. 11).

Thus, even distant metastases, presumably founded by a single migrant cancer cell, somehow become organized like the primary tumors, acquiring populations of stromal and inflammatory cells very similar to those found in the parent primary. This implies that the genetically deranged cancer cells in both the metastasis and the primary tumor must initiate and benefit from a complex choreography of mutual signaling and support. The detailed expression pattern appears to be characteristic, possibly even unique, for each independently arising cancer cell; the general pattern is characteristic of the particular cancer subtype. Particularly interesting in this context was the finding by Chen *et al.* (11) that, in the case of hepatocellular carcinoma, where an individual patient might have more than one independently arising tumor as well as metastases of some of them, only the clonally related tumors (on the basis of DNA changes) had similar expression profiles.

Here we describe the results of an experiment designed to address specifically the possibility that the stromal components are involved in some kind of “coevolution” with the tumor, by looking directly for alterations in the genomic DNA of stromal cells during the establishment of human tumors that result from the introduction of clones of malignant human tumor cell lines into nude mice. This cross-species design provided a secure way to distinguish the genetically human cancer cells from the putatively coevolving stromal helper cells. Tumors that arise in this system necessarily have stromal components derived from the mouse, even though the malignant founder cells are human. Any changes in stromal cell genomes would be changes in the mouse genome, and not the human genome.

We used representational oligonucleotide microarray analysis (ROMA), which has proven to be both sensitive and reliable, enabling the detection of copy number changes ranging from a few tens of kilobases to entire chromosome arms (12–14). Briefly, ROMA’s sensitivity is derived from its reduction of the complexity of the test and reference genomes analyzed ($\approx 3\%$ of the original genome) by making BglII genomic representations, consisting of small restriction fragments, between 200 and 1,200 base pairs. The BglII restriction fragments are then amplified by adaptor-mediated PCR, fluorescently labeled and the test and reference samples are hybridized to custom fabricated microarrays containing oligonucleotide probes to BglII fragments designed *in silico* from the mouse genome sequence assembly to be

Author contributions: R.J.P., M.W., and D.B. designed research; R.J.P. and L.R. performed research; I.H., R.L., K.C.Q.N., N.N., D.M., and S.P. contributed new reagents/analytic tools; R.J.P., I.H., J.H., M.W., and D.B. analyzed data; and R.J.P., M.W., and D.B. wrote the paper.

The authors declare no conflict of interest.

Freely available online through the PNAS open access option.

Abbreviations: ROMA, representational oligonucleotide microarray analysis; qPCR, quantitative PCR.

[†]To whom correspondence may be addressed. E-mail: rpelham@princeton.edu or botstein@princeton.edu.

This article contains supporting information online at www.pnas.org/cgi/content/full/0609635104/DC1.

© 2006 by The National Academy of Sciences of the USA




Fig. 2. Alterations in stromal DNA copy number identified by ROMA. (a) Amplification in EphA4. (b) Deletion in EphA4. (c) Deletion in Ubadc1. (d) Deletion in Ywha9 and Adam17. (e) Deletion in Opcl1. (f) Deletion in Hrrr. Copy number profile of stroma from tumor (blue) and normal reference DNA (orange) are indicated. Probe ratios are plotted on a \log_{10} scale.

were unambiguously confirmed by direct and flanking qPCR analysis (Table 1 and SI Table 2). Two of these alterations in copy number were amplifications, and 15 were deletions (Table 1).

Individual Genes Altered in DNA Copy Number in Tumor Stroma. A summary is provided of some of the amplification and deletion events whose known biology is of particular interest with respect

to carcinogenesis or cancer progression (see *SI Text*). A complete list of all of the PCR-confirmed events is found in Table 1.

The single most notable event occurred in the stroma of a xenograft tumor (BOT0011) caused by the human colorectal carcinoma cell line HCT-15, which contained a 2.8-fold amplification of the gene encoding EphA4 (Fig. 2a and Table 1). Interestingly, the stroma of a second xenograft tumor (BOT0018) caused

Table 1. Alterations in stromal DNA copy number validated by qPCR

Gene symbol(s)	Gene name(s)	Change in copy number	Relative copy number ($2^{\Delta Ct}$)	Band	Deletion/amplicon size, kb	Sample name	Tumor type	Name of xenograft tumor
Adamdec1	ADAM-like (decysin 1)	Loss	0.42	14D1	256.56	BOT0026	Breast	MDA-MB-231
EphA4	Eph receptor A4	Gain	2.84	1qC4	31.22	BOT0011	Colon	HCT-15
EphA4	Eph receptor A4	Loss	0.43	1qC4	31.22	BOT0018	Breast	MDA-MB-435s
Hrnr	Hornerin	Loss	0.17	3qF2.1	6.89	BOT0020	Colon	HCT-15
Hrnr	Hornerin	Loss	0.40	3qF2.1	6.89	BOT0028	Breast	MDA-MB-435s
Ighg	Immunoglobulin heavy chain (gamma polypeptide)	Loss	0.29	12qF1	553.54	BOT0029	Breast	MDA-MB-435s
Ighg	Immunoglobulin heavy chain (gamma polypeptide)	Loss	0.21	12qF1	553.54	BOT0031	Breast	MDA-MB-435s
Kcnd2	Potassium voltage-gated channel, Shal-related family, member 2 (Kv4.2)	Gain	2.40	6qA2	69.48	BOT0028	Breast	MDA-MB-435s
Mup1; Mup2	Major urinary protein 1; Major urinary protein 2	Loss	0.26, 0.26	4qB3	860.02	BOT0029	Breast	MDA-MB-435s
Mup1; Mup2	Major urinary protein 1; Major urinary protein 2	Loss	0.10, 0.14	4qB3	860.02	BOT0031	Breast	MDA-MB-435s
Opcml	Opioid binding protein/cell adhesion molecule-like	Loss	0.16	9qA4	672.87	BOT0031	Breast	MDA-MB-435s
Rabgap1	RAB GTPase activating protein 1	Loss	0.28	2qB	20.77	BOT0028	Breast	MDA-MB-435s
Ubadc1	Ubiquitin associated domain containing 1 (putative glioblastoma cell differentiation-related)	Loss	0.37	2qA3	16.13	BOT0028	Breast	MDA-MB-435s
Ubadc1	Ubiquitin associated domain containing 1 (putative glioblastoma cell differentiation-related)	Loss	0.14	2qA3	16.13	BOT0029	Breast	MDA-MB-435s
Ubadc1	Ubiquitin associated domain containing 1 (putative glioblastoma cell differentiation-related)	Loss	0.18	2qA3	16.13	BOT0031	Breast	MDA-MB-435s
V2r14; V2r15; V2r4	Vomer nasal 2, receptor, 14; Vomer nasal 2, receptor, 15; Vomer nasal 2, receptor, 4	Loss	0.43, 0.43, 0.06	7qA1	1769.45	BOT0031	Breast	MDA-MB-435s
Ywhaq; Adam17	Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta polypeptide; Disintegrin and metallopeptidase domain 17	Loss	0.06, 0.06	12qA1.2–1.3	2718.49	BOT0020	Colon	HCT-15

by the human breast carcinoma cell line MDA-MB-435s contained a 0.43-fold deletion in EphA4 (Fig. 2*a* and Table 1). In the ROMA survey, this amplification and deletion were both identified as single-probe events, and based on PCR, the nearest unamplified probes were 31.22 kb apart (Table 1). EphA4 is a receptor tyrosine kinase that belongs to a large family of Ephrin receptors. Although primarily involved in mediating developmental events directed by Ephrin (17), particularly in the nervous system, many studies have indicated a direct role for the ephrins and their receptors in tumor progression and angiogenesis (18). Increased expression of Ephrins and their receptors have been correlated with survival and invasive capacity of colorectal and ovarian cancers (19–21). Additionally, EphA2 and EphB2 have emerged as attractive drug targets for cancer therapy (22, 23). That EphA4 was observed as both amplification and deletion in the stroma caused by two different cell lines may be related to differences in the parental tumor cell lines as well as the anatomical location of the xenograft tumors (s.c. versus i.p.).

Discussion

The data summarized above and in Table 1 show that there are occasional DNA copy number changes in stromal cells of

xenograft tumors in nude mice caused by the introduction of cells from cloned human cancer cell lines. The DNA copy number changes are widely dispersed through the mouse genome and include both amplifications and deletions. Genes within the generally quite short regions of DNA that are altered (average length of 497.6 kb) include several whose biology (e.g., EphA4 and Adam17) is immediately interesting with respect to their potential roles in cancer. A few alterations appear in more than one independent tumor (e.g., Hornerin, Ubadc1, and EphA4) and in two cases, the causative cell lines were different.

There are several features to note about our detection of DNA alterations in tumor stromal cells.

1. Our experimental design allowed us to separate cleanly stromal cells from the causative cancer cells. There was no indication in the FACS-sorting step of possible mouse–human hybrid nuclei (24, 25), nor was there any human genetic material detected in the DNA from the isolated mouse nuclei (SI Fig. 3). The changes we detected are not present in the parental human tumors (data not shown).
2. Our detection of any changes at all (especially the deletions) implies that there may indeed be a clonal selection process

DNA as reference were hampered by significant background noise, likely the result of the early stages of apoptosis in the xenograft tumor and stromal DNA degradation (SI Fig. 4*a*). This obstacle was overcome by performing the ROMA analysis in two stages: (i) Comparison of stromal nuclei from one xenograft tumor with the stromal nuclei of a second xenograft tumor; both xenograft tumors were caused by the same human tumor cell line and thus shared the same pattern of DNA degradation. This step significantly reduced background noise and allowed for the identification of DNA copy number changes in stromal DNA. (ii) Comparison of tail DNA from the mice used in the stromal analysis. This stage accounted for any genetic differences between these outbred individual mice, and facilitated the isolation of bona fide DNA copy number changes in the stroma from other genetic differences such as single-nucleotide or copy number polymorphisms (14). Additional details are available in SI Fig. 4.

Quantitative Real-Time PCR. qPCR primers and dual-labeled fluorogenic probes used to validate candidate copy number alterations were designed *in silico* from the mouse genome, NCBI Build 33, and manufactured by Sigma-Prologo (Woodlands, TX) or Integrated DNA Technologies (Coralville, IA). Primer/probe sequences are available in SI Table 3. DNA copy number was quantified by using the Applied Biosystems 7900 sequence detection system (Applied Biosystems, Foster City, CA), and the data were analyzed with SDS 2.1 software (Applied Biosystems) using standard protocols.

Candidate copy number alterations based on 1–2 probe events in ROMA (e.g., EphA4) were validated by using qPCR probes to three distinct regions of the candidate gene. Probes were designed to: (i) the BglII fragments producing the probe event in ROMA, (ii) regions proximal to the BglII fragments, but still

within the candidate gene, and (iii) genes directly flanking the candidate gene. Large candidate copy number alterations (>10 probe events, e.g., Adam17) were validated by using qPCR probes to regions within the ROMA prediction, but not specifically to the BglII fragments.

The relative gene copy numbers were derived by using the formula $2^{\Delta Ct}$, where ΔCt is the difference in amplification cycles required to detect amplification product from equal starting concentrations of matched reference tail or skin genomic DNA as compared with genomic DNA from mouse stromal nuclei isolated from gross dissected xenograft tumors (44). β -Actin was used as a reference probe for normalization. PCRs were performed in quadruplicate, and copy number alterations were scored as validated if $2^{\Delta Ct}$ (relative copy number) was ≥ 1.5 (gain) or ≤ 0.5 (loss) with CV $\leq 15\%$ of mean $2^{\Delta Ct}$.

We are grateful for the assistance of Pam Moody and Jennifer Meth with FACS analysis of stromal and tumor nuclei. Lisa Bianco and the staff of the Cold Spring Harbor Animal Facility provided invaluable support throughout this study. Dr. Peter Siegel (McGill University, Montreal, QC, Canada) provided extensive training in the use of mice as a model system. We thank Drs. Vladimir Grubor, Lakshmi Muthuswamy, members of the Wigler Laboratory and the Cold Spring Harbor Laboratory community-at-large for helpful discussions and kind support. R.J.P. thanks Dr. Becket Feierbach for her love, patience, and support throughout this study. This work was supported by National Institutes of Health Grant 5R01-CA078544-07; Department of the Army Grants W81XWH-06-1-0189, W81XWH04-1-0477, W81XWH-05-1-0068, and W81XWH-04-0905; grants from Miracle Foundation, Breast Cancer Research Foundation, Long Islanders Against Breast Cancer, West Islip Breast Cancer Foundation, Long Island Breast Cancer (1 in 9), and The Karches Foundation; an Elizabeth McFarland Breast Cancer Research Grant; and a grant from Breast Cancer Help, Inc. (to M.W.). M.W. is an American Cancer Society Research Professor.

- Hanahan D, Weinberg RA (2000) *Cell* 100:57–70.
- Bissell MJ, Radisky D (2001) *Nat Rev Cancer* 1:46–54.
- Coussens LM, Werb Z (2002) *Nature* 420:860–867.
- Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, Chi JT, van de Rijn M, Botstein D, Brown PO (2004) *PLoS Biol* 2:E7.
- Dvorak HF (1986) *N Engl J Med* 315:1650–1659.
- Perou CM, Sørli T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. (2000) *Nature* 406:747–752.
- Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M, van de Rijn M, Rosen GD, Perou CM, Whyte RI, et al. (2001) *Proc Natl Acad Sci USA* 98:13784–13789.
- Sørli T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2001) *Proc Natl Acad Sci USA* 98:10869–10874.
- Sørli T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al. (2003) *Proc Natl Acad Sci USA* 100:8418–8423.
- Weigelt B, Hu Z, He X, Livasy C, Carey LA, Ewend MG, Glas AM, Perou CM, van't Veer LJ (2005) *Cancer Res* 65:9155–9158.
- Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, Lai KM, Ji J, Dudoit S, Ng IO, et al. (2002) *Mol Biol Cell* 13:1929–1939.
- Sebat J, Lakshmi B, Troge J, Alexander J, Young J, Lundin P, Maner S, Massa H, Walker M, Chi M, et al. (2004) *Science* 305:525–528.
- Lucito R, Healy J, Alexander J, Reiner A, Esposito D, Chi M, Rodgers L, Brady A, Sebat J, Troge J, et al. (2003) *Genome Res* 13:2291–2305.
- Lakshmi B, Hall IM, Egan C, Alexander J, Leotta A, Healy J, Zender L, Spector MS, Xue W, Lowe SW, et al. (2006) *Proc Natl Acad Sci USA* 103:11234–11239.
- Goossens T, Klein U, Kuppers R (1998) *Proc Natl Acad Sci USA* 95:2463–2468.
- Odegard VH, Schatz DG (2006) *Nat Rev Immunol* 6:573–583.
- Wilkinson DG (2001) *Nat Rev Neurosci* 2:155–164.
- Carmeliet P, Tessler-Lavigne M (2005) *Nature* 436:193–200.
- Clevers H, Batlle E (2006) *Cancer Res* 66:2–5.
- Guo DL, Zhang J, Yuen ST, Tsui WY, Chan ASY, Ho C, Ji J, Leung SY, Chen X (2006) *Carcinogenesis* 27:454–464.
- Jubb AM, Zhong F, Bheddah S, Grabsch HI, Frantz GD, Mueller W, Kavi V, Quirke P, Polakis P, Koeppen H (2005) *Clin Cancer Res* 11:5181–5187.
- Carles-Kinch K, Kilpatrick KE, Stewart JC, Kinch MS (2002) *Cancer Res* 62:2840–2847.
- Mao W, Luis E, Ross S, Silva J, Tan C, Crowley C, Chui C, Franz G, Senter P, Koeppen H, Polakis P (2004) *Cancer Res* 64:781–788.
- Duelli D, Lazebnik Y (2003) *Cancer Cell* 3:445–448.
- Jacobsen BM, Harrell JC, Jedlicka P, Borges VF, Varella-Garcia M, Horwitz KB (2006) *Cancer Res* 66:8274–8279.
- Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA (2005) *Cell* 121:335–348.
- Schmeichel KL, Bissell MJ (2003) *J Cell Sci* 116:2377–2388.
- West RB, Nuyten DSA, Subramanian S, Nielsen TO, Corless CL, Rubin BP, Montgomery K, Zhu S, Patel R, Hernandez-Boussard T, et al. (2005) *PLoS Biol* 3:e187.
- Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, et al. (2004) *Cancer Cell* 6:17–32.
- Ferrara N, Gerber H-P, LeCouter J (2003) *Nat Med* 9:669–676.
- Ferrara N, Kerbel RS (2005) *Nature* 438:967–974.
- Dong J, Grunstein J, Tejada M, Peale F, Frantz G, Liang WC, Bai W, Yu L, Kowalski J, Liang X, Fuh G, Gerber HP, Ferrara N (2004) *EMBO J* 23:2800–2810.
- Tejada ML, Yu L, Dong J, Jung K, Meng G, Peale FV, Frantz GD, Hall L, Liang X, Gerber H-P, Ferrara N (2006) *Clin Cancer Res* 12:2676–2688.
- Tuhkanen H, Anttila M, Kosma VM, Yla-Herttuala S, Heinonen S, Kuronen A, Juhola M, Tammi R, Tammi M, Mannermaa A (2004) *Int J Cancer* 109:247–252.
- Paterson RF, Ulbright TM, MacLennan GT, Zhang S, Pan CX, Sweeney CJ, Moore CR, Foster RS, Koch MO, Eble JN, Cheng L (2003) *Cancer* 98:1830–1836.
- Matsumoto N, Yoshida T, Yamashita K, Numata Y, Okayasu I (2003) *Br J Cancer* 89:707–712.
- Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou, X-P, Eng C (2002) *Nat Genet* 32:355–357.
- Fukino K, Shen L, Matsumoto S, Morrison CD, Mutter GL, Eng C (2004) *Cancer Res* 64:7231–7236.
- Hu M, Yao J, Cai L, Bachman KE, van den Brule F, Velculescu V, Polyak K (2005) *Nat Genet* 37:899–905.
- Hill R, Song Y, Cardiff RD, Van Dyke T (2005) *Cell* 123:1001–1011.
- Hida K, Hida Y, Amin DN, Flint AF, Panigrahy D, Morton CC, Klagsbrun M (2004) *Cancer Res* 64:8249–8255.
- Liotta LA, Kohn EC (2002) *J Natl Cancer Inst* 94:1113–1114.
- Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J, Speed TP (2002) *Nucleic Acids Res* 30:e15.
- Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, et al. (1998) *Nature* 396:699–703.